Ukraine proposes $100 bln US weapons deal for security guarantees - FT
Stephen P. Robertson, Executive Vice President and General Counsel at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a pharmaceutical company with a market capitalization of $1.1 billion and strong financial health according to InvestingPro, executed significant stock transactions recently. According to the latest SEC filing, Robertson sold a total of 122,479 shares across two transactions on March 3 and March 4. The shares were sold at prices ranging from $7.92 to $8.00, culminating in a total value of $975,223. The company’s current trading price of $8.08 reflects a 44% gain over the past year, with InvestingPro analysis suggesting the stock may be undervalued.
In addition to these sales, Robertson acquired shares on two different occasions without any cash transaction involved. On February 28, he acquired 84,106 shares, and on March 3, he acquired an additional 102,406 shares. These acquisitions were part of performance awards and employee stock options, which did not involve any direct monetary exchange.
Following these transactions, Robertson retains a significant holding in the company, with a total of 509,276 shares owned directly.
In other recent news, Aurinia Pharmaceuticals reported its fourth-quarter 2024 earnings, missing analysts’ expectations. The company announced an earnings per share (EPS) of $0.01, which fell short of the anticipated $0.03. Revenue for the quarter also came in below forecasts at $59.9 million, compared to the projected $61.7 million. Despite these misses, Aurinia Pharmaceuticals experienced a 34% increase in total revenue for the year, reaching $235.1 million. The company’s flagship product, LUKINIS, reported net product sales of $57.6 million for the fourth quarter, marking a 36% increase year-over-year. Looking ahead, Aurinia Pharmaceuticals has set a total revenue guidance for 2025 between $250 million and $260 million. The company is also advancing its pipeline with AUR200, with initial results from a Phase 1 study expected in the second quarter of 2025. Additionally, Aurinia Pharmaceuticals remains focused on expanding its market presence and product offerings, as stated by CEO Peter Greenleaf.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.